SLU PP 332 for Sale USA: A Complete Sourcing Guide

Disclaimer: All articles and product details provided on this website are intended for educational and informational purposes only. The products listed here are for in-vitro research only. In-vitro studies are conducted outside of living organisms. These products are not intended as medicines or drugs and have not been approved by the FDA to prevent, treat, or cure any medical condition, ailment, or disease. The direct or indirect administration of these substances to humans or animals is unequivocally prohibited under applicable law.

If you are sourcing SLU-PP-332 for laboratory work in the United States, two things decide whether the material is usable: what the molecule actually is, and whether the specific batch in front of you has been independently verified. This guide covers both — the published mechanism, then a concrete checklist for evaluating a supplier and a certificate of analysis.

One correction worth making up front, because it appears widely and it matters for handling: SLU-PP-332 is not a peptide. It is a synthetic small molecule. Sources that describe it as a “10–30 amino acid chain” are wrong, and storage and stability advice built on that assumption should be treated with suspicion.

Key takeaways

• SLU-PP-332 is a synthetic small molecule, not a peptide. It is a pan-agonist of the estrogen-related receptors with greatest potency at ERRα.
• The mechanism is demonstrated, not assumed: ERRα knockout mice lose the endurance effect.^[1]
• All published efficacy work is in cell lines and mice. No human clinical trial has been published.
• The one document that determines whether a batch is usable is a lot-matched, third-party certificate of analysis.
• It has a short half-life and degrades on repeated freeze–thaw — aliquot on first reconstitution.

What is SLU-PP-332?

SLU-PP-332 is a synthetic pan-agonist of the estrogen-related receptors (ERRs) — ERRα, ERRβ and ERRγ — developed as a pharmacological tool molecule in the Burris laboratory at Saint Louis University, which is where the “SLU” prefix comes from. It has the highest reported potency at ERRα.^[1]

The ERRs are orphan nuclear receptors. Unlike the estrogen receptor, which they resemble structurally, they have no known endogenous ligand and they are not activated by estrogen. Their principal role is transcriptional control of mitochondrial biogenesis and oxidative metabolism, largely through partnership with the co-activator PGC-1α.^[3] That makes them a plausible pharmacological entry point into the metabolic programme normally switched on by endurance exercise.

How does it work as an exercise mimetic?

The term “exercise mimetic” is doing specific work here, and it is narrower than it sounds. SLU-PP-332 binds the ERR ligand-binding domain, stabilises the active conformation and enhances co-activator recruitment. The downstream transcriptional programme upregulates genes involved in oxidative phosphorylation, fatty acid β-oxidation and glucose handling — a shift toward fat as the preferred fuel source.

In the foundational 2023 characterisation, SLU-PP-332 increased mitochondrial function and cellular respiration in a skeletal muscle cell line. Administered to mice, it increased type IIa oxidative muscle fibres and enhanced exercise endurance, and it induced an ERRα-specific acute aerobic exercise gene programme. Critically, the study used ERRα knockouts to show that ERRα activation was required for the endurance effect — the mechanism is not inferred, it is demonstrated by loss of function.^[1]

A follow-up study reported that the molecule alleviated features of metabolic syndrome in a mouse model.^[2] Both papers describe rodent and cell work. There is no published human clinical trial of SLU-PP-332.

What is it used to study?

• Mitochondrial biogenesis and oxidative capacity — the core readout, measured by respiration assays and mitochondrial gene expression.
• Fuel selection — the shift from glucose toward fatty acid oxidation, and what that does to energy expenditure.
• Skeletal muscle fibre type — whether pharmacological ERRα activation reproduces the fibre-type adaptation seen with endurance training.
• Metabolic syndrome models — adiposity, glucose tolerance and lipid handling in diet-induced obesity.
• Nuclear receptor pharmacology — ERRα/β/γ selectivity, since few well-characterised ERR ligands exist.

One practical note for study design: SLU-PP-332 has a short half-life, which is why the published rodent work uses frequent dosing. Its analytical characterisation, alongside the related molecule SLU-PP-915, has also been examined in the anti-doping literature — useful if you need validated detection methods.^[4]

Research material

Why does purity decide the result?

Reproducibility depends on knowing exactly what went into the experiment. A molecule sold at 85% purity has 15% of something unspecified in it, and any effect you measure could belong to that 15%. For a receptor-targeted tool molecule this is worse than usual: contaminants with their own nuclear receptor activity will confound precisely the readout you are trying to isolate.

Purity also governs concentration accuracy. If the stated mass is 20% filler, every concentration in your protocol is wrong by 20%, and dose-response curves from different lots will not line up.

Why third-party testing rather than in-house

In-house testing is a reasonable first pass, but the supplier has an interest in the result. Sending material to an independent laboratory removes that conflict. The document you want is a certificate of analysis produced by a lab that has no commercial relationship with the outcome.

How to read a certificate of analysis

Most COAs look convincing at a glance. Check these five things:

• Lot number match. The lot on the COA must match the lot printed on the container you received. A generic COA for the product line proves nothing about your batch.
• Identity confirmation. Mass spectrometry confirming the expected molecular weight. This is what proves the molecule is what the label says.
• Purity by HPLC. Look for the actual chromatogram, not just a percentage. The trace shows you where the impurities sit.
• Test date and laboratory name. A named, contactable laboratory and a date close to the production run.
• Method detail. Column, mobile phase, detection wavelength. Vague methodology usually means vague results.

How do you vet a US supplier?

A short checklist that separates suppliers quickly:

• Batch-specific COAs published or provided on request — the single most informative signal.
• Lot numbers on the container, traceable back to the COA.
• Clear research-use-only positioning. A supplier making health claims about a research molecule is telling you how seriously they take compliance.
• Documented storage and shipping conditions, including how temperature-sensitive material is handled in transit.
• Consistent product identity across listings — if the same molecule is described as a peptide on one page and a small molecule on another, nobody there is checking.
• Responsive technical support that can answer a question about a chromatogram rather than routing it to sales.
• A stated return policy covering material that arrives compromised.

Price versus purity

Price differences between suppliers usually reflect testing depth, not margin. Independent analysis of every lot costs money and it shows up in the price. The relevant comparison is not price per milligram — it is cost per usable experiment. A cheap lot that fails identity confirmation, or forces you to repeat a run, is the expensive option.

How should SLU-PP-332 be stored and handled?

• Long-term storage. Keep the material at −20 °C, protected from light and moisture. In dry form it is comparatively stable.
• After reconstitution. Shelf life shortens considerably. Store refrigerated, in the dark, and label the vial with the reconstitution date and solvent.
• Aliquot rather than re-freeze. Repeated freeze–thaw cycles degrade material and introduce lot-to-lot variation inside a single lot.
• Equilibrate before opening. Let a frozen vial reach room temperature before breaking the seal, or condensation will enter it.
• Standard laboratory PPE. Gloves, eye protection, lab coat; handle powders in a way that avoids aerosolisation.

What are the compliance requirements?

SLU-PP-332 is supplied strictly for in-vitro research use. It has not been approved by the FDA or any comparable regulator for use as a drug or a supplement, and its safety profile in humans is not established. Administration to humans or animals is prohibited.

For a laboratory receiving it, the practical obligations are ordinary but non-negotiable: purchase through an institutional or documented research account; maintain records of receipt, lot number, storage location and use; keep the COA on file with the experimental record; and dispose of surplus material through your institution’s chemical waste stream rather than general refuse. If you are moving material across a border, confirm the import rules for that jurisdiction before shipping — research-use status in the United States does not transfer automatically.

What belongs in your experimental record?

Documentation is what makes a result citable by someone else. At minimum, record against every run: supplier and lot number, COA reference, purity and identity results, reconstitution date, solvent and concentration, storage history including any freeze–thaw events, and the calculated concentration used. When two lots produce different results, this record is the only thing that will tell you why.

What the evidence does not show

It is worth being explicit about the boundary, because SLU-PP-332 is frequently described online in terms the literature does not support.

• No human data. There is no published clinical trial. Claims about effects in people are extrapolation from rodent work.
• No established safety profile. Long-term consequences of sustained pharmacological ERR activation — particularly in cardiac and metabolic tissue, and the oncologic vigilance that nuclear receptor agonism generally warrants — have not been characterised.
• No demonstrated body-composition effect in humans. Reduced adiposity has been reported in mouse models of metabolic syndrome.^[2] That is a model result.
• Claims of collagen, dermal or wound-healing activity are not supported. Several widely circulated articles cite studies in journals that do not exist. If a citation cannot be resolved to a DOI or a PubMed record, do not carry it into your own work.

That last point is the reason this guide lists only resolvable references below. The molecule is genuinely interesting on the strength of the real papers; it does not need the invented ones.

Frequently asked questions

Is SLU-PP-332 a peptide?

No. It is a synthetic small molecule pan-ERR agonist. The description of it as a short amino acid chain circulates widely online and is incorrect. This matters because peptide-specific handling advice does not necessarily apply.

Why is it called an “exercise mimetic”?

Because it activates ERRα and, through it, part of the same transcriptional programme that endurance exercise switches on in skeletal muscle — including a shift toward fat oxidation. It lets researchers isolate that metabolic programme in a controlled setting. It does not reproduce exercise, and the published work is in cells and mice.^[1]

Is SLU-PP-332 approved for human use?

No. It is a research molecule for qualified laboratory use only. It has not been approved by the FDA or any other regulator as a drug or supplement, and no human clinical trial has been published.

What makes it different from other metabolic research molecules?

Its target. Few well-characterised ERR ligands exist, and SLU-PP-332 activates all three ERR isoforms with greatest potency at ERRα. That gives researchers direct pharmacological access to a receptor family that was previously studied mostly through genetic models.

What is the single most important document to obtain?

The batch-specific certificate of analysis. It ties the material in your hand to independent identity and purity data. Without it you have an unlabelled input.

What is the biggest storage mistake?

Repeated freeze–thaw of a reconstituted vial. It degrades material silently — you get variable results from what you believe is a single consistent lot. Aliquot on first reconstitution and date every vial.

Sources

1. Billon C, Sitaula S, Banerjee S, et al. “Synthetic ERRα/β/γ agonist induces an ERRα-dependent acute aerobic exercise response and enhances exercise capacity.” ACS Chemical Biology, 2023;18(4):756–771. doi:10.1021/acschembio.2c00720
2. Billon C, Schoepke E, et al. “A synthetic ERR agonist alleviates metabolic syndrome.” Journal of Pharmacology and Experimental Therapeutics, 2024;388(2):232–240. doi:10.1124/jpet.123.001733
3. Audet-Walsh É, Giguère V. “The multiple universes of estrogen-related receptor α and γ in metabolic control and related diseases.” Acta Pharmacologica Sinica, 2015;36(1):51–61. doi:10.1038/aps.2014.121
4. “In vitro metabolism and analytical characterization of SLU-PP-332 and SLU-PP-915: novel pan-ERR agonists with doping potential.” PMC12835572

Related reading

• The FDA Peptide Ban List: What You Need to Know
• Achieving and Verifying Peptide Purity